RT Journal Article
SR Electronic
T1 Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4510
DO 10.1183/13993003.congress-2022.4510
VO 60
IS suppl 66
A1 R Prudente
A1 S Tanni
A1 M Okoshi
A1 F Damatto
A1 F Wehrmeister
A1 L Oliveira
A1 C Breda Neto
A1 L Pagan
A1 M Gatto
A1 L Vieira
A1 L Coelho
A1 D Rezende
A1 L Machado
A1 G Mota
A1 M Gaiato
A1 F Santaella
A1 E Campos
A1 L Hosoume
A1 E Franco
A1 U Weinreich
YR 2022
UL http://erj.ersjournals.com/content/60/suppl_66/4510.abstract
AB Background: Breathox® is a sodium chloride inhaler. Increase of the airway salinity has been proposed to reduce the symptomatic stage of a respiratory viral infection.Objective: to evaluate the effectiveness of nasal and inhaled sodium chloride therapy through Breathox® on mild COVID-19 symptoms in patients ≥ 18 years-old compared to usual care.Methods: a pilot, open, randomized clinical trial, including 100 patients with confirmed and symptomatic COVID-19 within 10 days of symptom onset. All patients received standard of care (SOC), i.e. antipyretic or analgesic. Breathox® was administered as two oral inhalations and one nasal instillation in each nostril at each administration with 2mg per inhalation. Patients were randomized 1:1:1 into three groups: Group 1(G1): SOC + Breathox® 10 times daily for 10 days; Group 2(G2): SOC + Breathox® five times daily for 10 days; Group 3(G3): SOC. Recovery time for symptoms, such as cough was assessed.Results: In total 100 of 103 screened patients were included from December 1 2021 to March 03 2022. Of those, 33 from G1 and G3, and 32 from G2 completed the study. Mean age was 40.4/42.2/40.6 years old for G1, G2 and G3, (p=0.96). No patients were hospitalized or died during the study. Time to cough resolution was reduced in G1 (2.8±0.66 days) and G2 (2.4±0.66 days) compared to G3 (5.39±0.79 days) (p=0.001), with a hazard ratio (HR) for G2 of 2.17 (Confidence interval 1.17-4.04) and G3 of 2.01 (1.06-3.81) compared to SOC.Conclusion: ten days of Breathox® use halved the time for resolution of COVID-19-induced cough.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 4510.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).